Compare ADMA Biologics Inc (ADMA) vs Symbotic Inc (SYM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Symbotic Inc — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Symbotic Inc trades at $40.95 (market cap $5.26B). The key difference: Symbotic Inc is far larger — about 2.5× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | SYM | |
|---|---|---|
Market Cap | $2.13B | $5.26B |
Sector | Health | Technology |
52-Week High | $20.38 | $87.30 |
52-Week Low | $7.60 | $38.57 |
Enterprise Value | $2.20B | $3.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
SYM trades at $44.46, up 4.02% in the last session, with a neutral technical signal and bearish moving averages. The stock shows mixed earnings, beating estimates in Q3 and Q4 2025 but missing in Q1 2026, while revenue grew to $2.25B in 2025. Recent news highlights the acquisition of ARMS Innovations, expanding its warehouse automation solutions, amid high investor interest in robotics stocks.
The outlook is cautiously optimistic with a consensus price target of $57.50, but risks include negative net income margins and high valuation multiples like EV/EBITDA of 246.96. Upside potential hinges on execution in the growing automation market, while downside risks involve competitive pressures and profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
